不同透析膜对血液透析患者外周血单个核细胞活化状态及氧化应激系统的影响
|
摘要
目的
研究不同透析膜对维持性血液透析(maintenance hemodialysis MHD)患者血浆及外周血单个核细胞(peripherial blood mononuclear cells PBMC)合成、分泌白细胞介素13(interleukin 13 IL-13)和白细胞介素18(interleukin 18 IL-18)水平以及氧化应激的影响;并判断IL-13、IL-18能否作为评价透析膜生物相容性的指标。
方法
将20名MHD患者随机分为纤维素生物膜组(650组)和聚砜膜组(F6组),每组各10例。应用酶联免疫吸附(enzyme linked immunosorbent assay ELISA)法测定MHD患者透析前、后血浆中以及PBMC经或未经刺激培养上清中IL-13、IL-18水平。采用半定量逆转录多聚酶链反应(Reverse Transcription PolymeraseChain Reaction RT-PCR)技术检测PBMC中IL-13、IL-18 mRNA的表达。同时选取30名MHD患者随机分为纤维素生物膜组(650组)、聚砜膜组(F6组)、维生素E包被透析膜(CL-E组),每组各10例。测定透析前、后血浆丙二醛(malondialdehyde MDA)、总抗氧化能力(total anti-oxidation capacity T-AOC)、晚期蛋白氧化产物(advanced oxidation protein products AOPP)、维生素E(VitaminE VitE)水平。另选取10名终末期肾病(end stage renal disease ESRD)未透析患者及10名健康成人作为对照组(control CON)。
结果
与正常对照组相比,ESRD未透析组及MHD组透析前血浆IL-13、IL-18水平明显升高(P＜0.05)。血液透析后,MHD各组的血浆IL-18水平无明显变化(P＞0.05),而IL-13水平明显下降(P＜0.05)。MHD患者血浆IL-13、IL-18水平与透析龄、KT/V均无相关性(P＞0.05)。PBMC受到刺激后,ESRD未透析组培养上清中IL-13和IL-18水平及其mRNA表达均明显下降(P＜0.05);650组培养上清中IL-13水平及mRNA表达无明显变化,而IL-18显著下降(P＜0.05);F6组培养上清中IL-13及IL-18水平及其mRNA表达均显著升高(P＜0.05),但升高幅度低于健康对照组。
ESRD未透析组血浆中MDA、AOPP水平较正常对照组明显升高(P＜0.05),T-AOC、VitE水平无明显变化(P＞0.05)。MHD各组透析前、后血浆AOPP水平无明显变化(P＞0.05);透析后T-AOC较透析前明显降低(P＜0.01);650及F6组透析前、后MDA水平无明显变化(P＞0.05),但650组透析前、后MDA水平明显高于ESRD未透析组(P＜0.05);CL-E组透析后MDA水平较透前明显降低(P＜0.05),VitE水平较透前明显升高(P＜0.05)。
结论
1、ESRD患者体内血浆IL-13、IL-18水平升高,证实ESRD患者处于微炎症状态。
2、HD不能降低IL-18水平,但可降低IL-13水平。提示HD进一步减弱了患者的抗炎能力。纤维素膜与聚砜膜之间无明显差异。
3、聚砜膜能改善PBMC对抗原的反应能力。故IL-13、IL-18可以作为判断透析膜的生物相容性的指标。
4、ESRD患者处于氧化应激状态,维生素E包被透析膜能改善MHD患者氧化应激状态。
Objective:
To investigate the plasma level of interleukin-13 (IL-13)、interleukin-18 (IL-18) and the effect of different dialysis membrane on peripheral blood mononuclear cells (PBMC) synthesis and release level of IL-13、IL-18 and the oxidative stress in patients with maintanence hemodialysis (MHD). To evaluate that if IL-I3、IL-18 can be biocompatibility indexes of dialyzer.
Methods:
The levels of IL-I3 and IL-18 in plasma and supernatants of PBMC cultured with or without stimulation were measured by enzyme linked immunosorbent assay (ELISA) method in all groups . The expression of IL-13 and IL-18 mRNA in PBMC were evaluated by reverse transcriptase polymerase chain reaction (RT-PCR). Patients in MHD groups were dialyzed with regenerated cellulose membrane (650 group) and polysulform membrane (F6 group) respectively. At the same time, thirty patients on MHD were divided into three groups randomly. The Patients were dialyzed with regenerated cellulose membrane (650 group)、polysulform membrane (F6 group) and Vitamin E-modified membrane (CL-E group)respectively. Blood samples were collected before and after dialysis to determine the concentrations of malonylaldehyde (MDA)、vitamin E (Vit E)、total anti-oxidation capacity (T-AOC)、advanced oxidation protein products (AOPP) in plasma. Ten healthy persons and ten end stage renal disease (ESRD) patients with non-hemodialysis were as controls(CON groups).
Results:
The plasma levels of IL-13、IL-18 in ESRD with non-hemodialysis group and MHD group before hemodialysis were higher significantly than those of healthy controls(P<0.05). After dialysis, the plasma levels of IL-18 were not obviously changed (P>0.05) and the plasma levels of IL-13 were decreased (P<0.05) in MHD groups. The plasma lever of IL-13, IL-18 and dialysis age , KT/V have no correlation (P>0.05). After PBMC were stimulated, the level of IL-13、IL-18 significantly decreased in ESRD with non-hemodialysis group (P<0.05); in 650 group, the level of IL-13 have no obviously changes (P>0.05) and the level of IL-18 decreased(P<0.05); the level of IL-13、IL-18 in F6 group significantly increased (P<0.05), but the increased levels were lower than that in healthy controls.
The plasma levels of MDA and AOPP in ESRD patients with no-dialysis were higher significantly than those of healthy controls (P<0.05). The plasma levels of T-AOC and VitE in ESRD patients with no-dialysis have no obviously changes than that in controls. The plasma levels of AOPP were no marked changes after dialysis in MHD groups (P<0.05), but obvious decline in T-AOC levels (P<0.01).There was no obviously changes in the levels of MDA in 650 group and F6 group after dialysis. The level of MDA was marked declined (P<0.05) and the level of VitE was increased (P>0.05) in CL-E group after dialysis.
Conclusion:
1、The plasma levels of IL-13、IL-18 in ESRD is higher than those of healthy controls. These suggest that the microinflammatory state is present in ESRD patients.
2、HD can not decrease the level of IL-18, but can decrease the level of IL-13. MHD can not improve the microinflammatory state, further damage the anti-inflammatory ability, and have no significant difference between cellulose and polysulform membrane.
3、The polysulform membranes can improve the immune function of PBMC. IL-13 and IL-18 can be biocompatibility indexes of dialyzer.
4、The oxidative stress is present in ESRD patients. VitE - modified membrane can improve the oxidative stress in MHD.
研究不同透析膜对维持性血液透析(maintenance hemodialysis MHD)患者血浆及外周血单个核细胞(peripherial blood mononuclear cells PBMC)合成、分泌白细胞介素13(interleukin 13 IL-13)和白细胞介素18(interleukin 18 IL-18)水平以及氧化应激的影响;并判断IL-13、IL-18能否作为评价透析膜生物相容性的指标。
方法
将20名MHD患者随机分为纤维素生物膜组(650组)和聚砜膜组(F6组),每组各10例。应用酶联免疫吸附(enzyme linked immunosorbent assay ELISA)法测定MHD患者透析前、后血浆中以及PBMC经或未经刺激培养上清中IL-13、IL-18水平。采用半定量逆转录多聚酶链反应(Reverse Transcription PolymeraseChain Reaction RT-PCR)技术检测PBMC中IL-13、IL-18 mRNA的表达。同时选取30名MHD患者随机分为纤维素生物膜组(650组)、聚砜膜组(F6组)、维生素E包被透析膜(CL-E组),每组各10例。测定透析前、后血浆丙二醛(malondialdehyde MDA)、总抗氧化能力(total anti-oxidation capacity T-AOC)、晚期蛋白氧化产物(advanced oxidation protein products AOPP)、维生素E(VitaminE VitE)水平。另选取10名终末期肾病(end stage renal disease ESRD)未透析患者及10名健康成人作为对照组(control CON)。
结果
与正常对照组相比,ESRD未透析组及MHD组透析前血浆IL-13、IL-18水平明显升高(P＜0.05)。血液透析后,MHD各组的血浆IL-18水平无明显变化(P＞0.05),而IL-13水平明显下降(P＜0.05)。MHD患者血浆IL-13、IL-18水平与透析龄、KT/V均无相关性(P＞0.05)。PBMC受到刺激后,ESRD未透析组培养上清中IL-13和IL-18水平及其mRNA表达均明显下降(P＜0.05);650组培养上清中IL-13水平及mRNA表达无明显变化,而IL-18显著下降(P＜0.05);F6组培养上清中IL-13及IL-18水平及其mRNA表达均显著升高(P＜0.05),但升高幅度低于健康对照组。
ESRD未透析组血浆中MDA、AOPP水平较正常对照组明显升高(P＜0.05),T-AOC、VitE水平无明显变化(P＞0.05)。MHD各组透析前、后血浆AOPP水平无明显变化(P＞0.05);透析后T-AOC较透析前明显降低(P＜0.01);650及F6组透析前、后MDA水平无明显变化(P＞0.05),但650组透析前、后MDA水平明显高于ESRD未透析组(P＜0.05);CL-E组透析后MDA水平较透前明显降低(P＜0.05),VitE水平较透前明显升高(P＜0.05)。
结论
1、ESRD患者体内血浆IL-13、IL-18水平升高,证实ESRD患者处于微炎症状态。
2、HD不能降低IL-18水平,但可降低IL-13水平。提示HD进一步减弱了患者的抗炎能力。纤维素膜与聚砜膜之间无明显差异。
3、聚砜膜能改善PBMC对抗原的反应能力。故IL-13、IL-18可以作为判断透析膜的生物相容性的指标。
4、ESRD患者处于氧化应激状态,维生素E包被透析膜能改善MHD患者氧化应激状态。
Objective:
To investigate the plasma level of interleukin-13 (IL-13)、interleukin-18 (IL-18) and the effect of different dialysis membrane on peripheral blood mononuclear cells (PBMC) synthesis and release level of IL-13、IL-18 and the oxidative stress in patients with maintanence hemodialysis (MHD). To evaluate that if IL-I3、IL-18 can be biocompatibility indexes of dialyzer.
Methods:
The levels of IL-I3 and IL-18 in plasma and supernatants of PBMC cultured with or without stimulation were measured by enzyme linked immunosorbent assay (ELISA) method in all groups . The expression of IL-13 and IL-18 mRNA in PBMC were evaluated by reverse transcriptase polymerase chain reaction (RT-PCR). Patients in MHD groups were dialyzed with regenerated cellulose membrane (650 group) and polysulform membrane (F6 group) respectively. At the same time, thirty patients on MHD were divided into three groups randomly. The Patients were dialyzed with regenerated cellulose membrane (650 group)、polysulform membrane (F6 group) and Vitamin E-modified membrane (CL-E group)respectively. Blood samples were collected before and after dialysis to determine the concentrations of malonylaldehyde (MDA)、vitamin E (Vit E)、total anti-oxidation capacity (T-AOC)、advanced oxidation protein products (AOPP) in plasma. Ten healthy persons and ten end stage renal disease (ESRD) patients with non-hemodialysis were as controls(CON groups).
Results:
The plasma levels of IL-13、IL-18 in ESRD with non-hemodialysis group and MHD group before hemodialysis were higher significantly than those of healthy controls(P<0.05). After dialysis, the plasma levels of IL-18 were not obviously changed (P>0.05) and the plasma levels of IL-13 were decreased (P<0.05) in MHD groups. The plasma lever of IL-13, IL-18 and dialysis age , KT/V have no correlation (P>0.05). After PBMC were stimulated, the level of IL-13、IL-18 significantly decreased in ESRD with non-hemodialysis group (P<0.05); in 650 group, the level of IL-13 have no obviously changes (P>0.05) and the level of IL-18 decreased(P<0.05); the level of IL-13、IL-18 in F6 group significantly increased (P<0.05), but the increased levels were lower than that in healthy controls.
The plasma levels of MDA and AOPP in ESRD patients with no-dialysis were higher significantly than those of healthy controls (P<0.05). The plasma levels of T-AOC and VitE in ESRD patients with no-dialysis have no obviously changes than that in controls. The plasma levels of AOPP were no marked changes after dialysis in MHD groups (P<0.05), but obvious decline in T-AOC levels (P<0.01).There was no obviously changes in the levels of MDA in 650 group and F6 group after dialysis. The level of MDA was marked declined (P<0.05) and the level of VitE was increased (P>0.05) in CL-E group after dialysis.
Conclusion:
1、The plasma levels of IL-13、IL-18 in ESRD is higher than those of healthy controls. These suggest that the microinflammatory state is present in ESRD patients.
2、HD can not decrease the level of IL-18, but can decrease the level of IL-13. MHD can not improve the microinflammatory state, further damage the anti-inflammatory ability, and have no significant difference between cellulose and polysulform membrane.
3、The polysulform membranes can improve the immune function of PBMC. IL-13 and IL-18 can be biocompatibility indexes of dialyzer.
4、The oxidative stress is present in ESRD patients. VitE - modified membrane can improve the oxidative stress in MHD.
引文
[1]中华医学会肾脏病分会透析移植登记工作组.1999年度全国透析移植登记报告.中华肾脏病杂志,2001,17(2):77-78.
[2]Schomig M,Eisenhandt A,Ritz E.The microinflammatory state of uremia.Blood Purif,2000,18(4):327-332.
[3]Angela C,Ashraf M,Mark WL,et al.Increased Expression of Erythropoiesis Inhibiting Cytokines(IFN-γ,TNF-α,IL-10 and IL-13)by T Cells in Patients Exhibiting a Poor Response to Erythropoietin Therapy.J Am Soc Nephrol,2003,14(5):1776-1784.
[4]J.Alastair Gracie,Rosalyn J.Forsey,Woon Ling Chan,et al.A Proinflammatory role for IL-18 in rheumatoid arthritis.J Clin Invest,1999,104(9):1393-1401.
[5]Monteleone G,Trapasso F,Parrello T,et al.Bioactive IL-18 expression is upregulated in Crohn's disease.J Immunol,1999,163(3):143-147.
[6]Kodama T,Matsuyama T,Kuribayashi K,et al.IL-18 deficiency selectively enhances allergen-induced eosinophilia in mice.J Allergy Clin Immunol,2000,105(1):45-53.
[7]Rothe H,Hausmann A,Casteels K,et al.IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1 dependent destructive insulitis.J Immunol,1999,163(3):1230-1236.
[8]Netea MG,Fantuzzi G,Kullberg BJ,et al.Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia.J Immunol,2000,164(5):2644-2648.
[9]Kikuchi T,Akasaki Y,Joki T,et al.Antitumor activity of interleukin 18 on mouse glioma cells.J Immunother,2000,23(2):184-189.
[10]Kluth DC,Rees AJ.Inhibiting inflammatory cytokines.Semin Nephrol.1996,16(6):576-582.
[11]Minty.A,Chalon.P,Derocq,J-M,et al.Interleukin 13 is a new human lymphokine regulating inflammatory and immune responses.Nature,1993,362:248-250.
[12]Okamura H,Tsutsi H,Komotsu T,et al.Cloning of a new cytokine that induces interferonγ.Nature,1995,378(6552):88-91.
[13]S Gangemi,A Mallamace,PL Minciullo,et al.Involvement of Interleukin-18 in Patients on Maintenance Haemodialysis.Am J Nephrol,2002,22(5-6):417-421.
[14]Peter Stencinkel.Inflammation in end-stage renal failure:could it be treated? Nephrol Dial Transplant,2002,17(Suppl 8):33-38.
[15]Uchimura T,Motomiya Y,Okamura H,et al.Marked Increases in Macrophage Colony-Stimulating Factor and Interleukin-18 in Maintenance Hemodialysis Patients:Comparative Study of Advanced Glycation End Products,Carboxymethyllysine and Pentosidine.Nephron,2002,90:401-407.
[16]Pereira BJG.10th annual meeting of the international society of blood purification.Blood Purif,1992,10(2):61-107.
[17]张毅,刘海燕,陈孝文,等.血液透析对慢性肾衰竭患者血浆白细胞介素13水平的影响.广东医学院学报,2003,21(2):115-117.
[18]Panichi V,Migliori M,De Pietro S,et al.C-reactive protein as a marker of chronic inflammation in uremic patients.Blood Purif,2000,18(3):183-190.
[19]毛海苹,朱兰英.透析膜对血浆细胞因子水平的影响及临床意义.肾脏病与透析移植杂志,1997,6(3):239-241.
[20]Witko-Sarsat V,Friedlander M,Capeillere-Blandin C,et al.Advanced oxidation protein products as a novel marker of oxidative st ress in uremia.Kidney Int,1996,49(5):1304-1313.
[21]Miyata T,Van Y,Kurokawa K,et al.Alterations in non-enzymatic biochemistry in uremia:Origin and significance of carbonyl stress in long-term uremia complications.Kidney Int,1999,55(2):389-399.
[22]Schetter V,Wieland E,Methe H,et al.Oxidative stress during dialysis:effect on ftee radical scavenging enzyme(FRSE)activities and glutathione(GSH)concentration in granulocytes.Nephrol Dial Transplant,1998,13(10):2588-2593.
[23]叶云浩,倪兆慧,钱家麒,等.终末期肾病微炎症状态和动脉粥样硬化的关系.中华肾脏病杂志,2004,20(3):173-176.
[24]Jan G.Oxidative strees in chronic renal failure.Nephrol Dial Transplant,2001,16:2135-2137.
[25]Pupim LB,Himmelfarb J,Mcmonagle E,et al.Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress.Kidney Int,2004,65(6):2371-2379.
[26]Kaysen GA.C-reactive protein:a story half told.Semin Dial,2000,13(3):143-146.
[27]Hou FF,Owen WF.Beta 2-microglobulin amyloidosis:role of monocytes/macrophages.Curr Opin Nephrol Hypertens,2002,11(4):417-421.
[28]余月明,侯凡凡,张训,等.慢性肾衰竭患者同型半胱氨酸血症氧化应激和微炎症反应间的关系及其在动脉粥样硬化中的作用.中华内科杂志,2004,43(4):292-295.
[29]Yukawa S,Mune M,Otani H.Vitamin E disturbances in chronic renal failure.Nippon Rinsho,1999,57(10):2366-2370.
[30]Witko-Sarsat V,Gausson V,Descamps-Latscha B,et al.Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 2003,84(5):11-14.
[31]梁敏,候凡凡,陈瑗.化学修饰蛋白质类尿毒症毒素的检测方法与评价.中华肾脏病杂志,2003,19:190-191.
[32]Kalousova M,Zima T,Tesar V,et al.Advanced glycation and products and advanced oxidation protein in hemodialyzed patients.Blood Purif,2002,20(6):531-536.
[33]Witko-Sarsat V,Friedlander M,Capeillere-Blandin C et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int,1996,49(5):1304-1313.
[34]Drueke T,Witko-Sarsat V,Massy ZA,et al.Iron Therapy,advanced oxidation protein products.and carotid artery intima media thickness in end stage renal disease.Circulation,2002,106(17):2212.
[35]Witko-Sarsat V,Friedlander M,Nguyen Khoa T,et al.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol,1998,161:2524-2532.
[36]彭侃夫,吴雄飞,王军霞,等.大剂量维生素C预冲透析器对血液透析患者晚期氧化蛋白产物的影响.中国血液净化,2006,5(6):311-346.
[37]Jonathan H,Stenvinkel P,Ikizler TA,et al.The elephant in uremia:Oxidant stress as a unifying concept of cardiovascular disease in uremia.Kidney Int,2002,62(5):1524-1538.
[38]Azzi A,Boscoboinik D,Hensey C.The protein kinase C family.Eur J Biochem,1992,208:547-557.
[39]Yoshikawa T,Yoshida N.Vitamin E and leucocyte-endothelial cell interaction.Antioxid Redox Signal,2000,2(4):821-825.
[40]Canaud B,Cristol J.-P,Morena M,et al.Imbalance of oxidants and antioxidants in heamodialysis patients.Blood Purif,1999,17(2-3):99-106.
[41]Miyazaki H,Matsuoka H,Itabe H,et al.Hemodialysis impairs endothelial function via oxidative stress:Effect of vitamin E-coated dialyzer.Circulation,2000,101(9):1002-1006.
[42]Omata M,Higuchi C,DemuraR,et al.Reduction of neutrophil activation by vitamin E modified dialyzer membranes.Nephron,2000,85(3):221-231.
[43]梁敏,刘俊,候凡凡,等.维生素E包被膜透析器对血透患者氧化状态的影响.中华肾脏病杂志,2003,19(4):259-260.
[44]Cristol JP,Bosc JY,Badiou S,et al.Erythropoietin and oxidative stress in haemodialysis:benefical effects of vitamin E supplemention.Nephrol Dial Transplant,1997,12(11):2312-2317.
[45]赵轶雯,王质刚.维生素E修饰的透析膜抗氧化作用临床研究.中国实用内科,2004,24(8):479-481.
[1]王海燕.慢性肾脏疾病防治的新概念.现代实用医学,2004,16(12):691-693.
[2]Giovanm,Pertosa,Giuseppe Grandaliano,et al.IL-6,IL-8,monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes.Kidney Int,1998;54:570-579.
[3]Yan-HD et al.Hemodialysis-related induction of interleukin-6 and interleukin-8 production by peripheral blood mononuclear cells.Hong Kong Journal of Nephrology 2001;3(1):33-37.
[4]严海东,李曼,钱正子,等.不同透析膜对血液透析患者外周血单个核细胞分泌IL-10的影响.中国医科大学学报,2001,30(2):144-146.
[5]许勇芝,唐德燊,梁东,等.慢性肾衰患者外周血IL-18水平及血液透析对其的影响.上海免疫学杂志,2003,23(1):50-52.
[6]Kawakami K.Interleukin-18 and host defense against infectiouspathogens.J Immunother,2002,25(Suppl 1):S12.
[7]Lebel-Binay S,Berger A,Zinzindohoue F,et al.Interleukin-18:biological properties and clinical implications.Eur Cytokine Netw,2000,11(1):15.
[8]Ahn HJ,Maruo S,Tomura M,et al.A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.J Immunol,1997,159(5):2125-2131.
[9]Barbulesou K,Becker C,Schlaak J F,et al.IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-γ promoter in primary CD4+T lymphocytes.J Immunol,1998,160(8):3642-3647.
[10]Smeltz RB,Chen J,Huli J,et al.Regulation of interleukin(IL)-18 receptor alpha chain expression on CD4(+)T cells during T helper(Th)1/Th2 differentiation.Critical downregulatory role of IL-4[J].J Exp M ed 2001,194(2):143-153.
[11]Son YI,Dallal RM,Mailliard RB,et al.Interleukin-18(IL-18)synergizes with IL-12 to enhance cytotoxicity,intergamma production and expansion of natural killer cells.Cancer Res,2001,61(3):884-888.
[12]Hashimoto W,Tanaka F,Robbins PD,et al.Natural killer,but not natural killer T,cells play a necessary role in the promotion of an innate antitumor response induced by IL-18.Int J Cancer,2003,103(4):508.
[13]CARMELO LIBETTA,et al.Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients Kidney International,2004,65:1473-1481.
[14]Di Felice A,Cappelli G,Facchini F,et al.Ultrafiltration and endotoxin removal from dialysis fluids.Kidney int,1993,41:201.
[15]Lufft V,Mahiout A,Shaldon S,et al.Retention of cytokine inducing substances inside high-flux dialyzers.Blood Purif,1996,14(1):26.
[16]Gerdes N,Sukhova GK,Libby P,et al.Expression of interleukin IL-18 and function IL-18receptor on human vascular endothelial cells,smooth muscle cells,and macrophages:implications for atherogenesis.J Exp Med,2002,195:245-257.
[17]Whitman SC,Ravisankar P,Elam H,et al.Exogenous interferon gamma enhances atherosclerosis in apolipoprotein E2/mice.Am J Pathol,2000,157(6):1819-1824.
[18]Zaremba J,Losy J.Interleukin-18 in acute ischaemic stroke patients[J].Neurol Sci,2003,24(3):17-24.
[19]朱志先,梁虹.现代心身疾病治疗学.北京:人民军医出版社,2002:197-197.
[20]Jiang Y,Harlocker SL,Molesh DA,et al.Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.Oncogene,2002,21(14):2270-2282.
[21]刘华峰,陈孝文等.原发性肾小球肾炎患者组织白介素18的表达.中华肾脏病杂志,2003,19(2):127-128.
[22]Melnikov VY,Ecder T,et al.Impaired IL-18 processing pretect caspase-1-deficient mice from ischemic acute renal failure[J].Clin Invest,2001,107(9):1145-1152
[23]Matsumoto K,Kanmatsuse K.Augmented interleukin 18 production by peripheral blood monocytes in patients with minimal change nephritic syndrome[J].Am J Nephrol, 2001,21(1):20-27.
[24] Mstsumoto K, Kanmatsuse K, Elevated interleukin-18 levels in the urine of nephritic patients[J]. Nephron, 2001,88(4):334-339.
[2]Schomig M,Eisenhandt A,Ritz E.The microinflammatory state of uremia.Blood Purif,2000,18(4):327-332.
[3]Angela C,Ashraf M,Mark WL,et al.Increased Expression of Erythropoiesis Inhibiting Cytokines(IFN-γ,TNF-α,IL-10 and IL-13)by T Cells in Patients Exhibiting a Poor Response to Erythropoietin Therapy.J Am Soc Nephrol,2003,14(5):1776-1784.
[4]J.Alastair Gracie,Rosalyn J.Forsey,Woon Ling Chan,et al.A Proinflammatory role for IL-18 in rheumatoid arthritis.J Clin Invest,1999,104(9):1393-1401.
[5]Monteleone G,Trapasso F,Parrello T,et al.Bioactive IL-18 expression is upregulated in Crohn's disease.J Immunol,1999,163(3):143-147.
[6]Kodama T,Matsuyama T,Kuribayashi K,et al.IL-18 deficiency selectively enhances allergen-induced eosinophilia in mice.J Allergy Clin Immunol,2000,105(1):45-53.
[7]Rothe H,Hausmann A,Casteels K,et al.IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1 dependent destructive insulitis.J Immunol,1999,163(3):1230-1236.
[8]Netea MG,Fantuzzi G,Kullberg BJ,et al.Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia.J Immunol,2000,164(5):2644-2648.
[9]Kikuchi T,Akasaki Y,Joki T,et al.Antitumor activity of interleukin 18 on mouse glioma cells.J Immunother,2000,23(2):184-189.
[10]Kluth DC,Rees AJ.Inhibiting inflammatory cytokines.Semin Nephrol.1996,16(6):576-582.
[11]Minty.A,Chalon.P,Derocq,J-M,et al.Interleukin 13 is a new human lymphokine regulating inflammatory and immune responses.Nature,1993,362:248-250.
[12]Okamura H,Tsutsi H,Komotsu T,et al.Cloning of a new cytokine that induces interferonγ.Nature,1995,378(6552):88-91.
[13]S Gangemi,A Mallamace,PL Minciullo,et al.Involvement of Interleukin-18 in Patients on Maintenance Haemodialysis.Am J Nephrol,2002,22(5-6):417-421.
[14]Peter Stencinkel.Inflammation in end-stage renal failure:could it be treated? Nephrol Dial Transplant,2002,17(Suppl 8):33-38.
[15]Uchimura T,Motomiya Y,Okamura H,et al.Marked Increases in Macrophage Colony-Stimulating Factor and Interleukin-18 in Maintenance Hemodialysis Patients:Comparative Study of Advanced Glycation End Products,Carboxymethyllysine and Pentosidine.Nephron,2002,90:401-407.
[16]Pereira BJG.10th annual meeting of the international society of blood purification.Blood Purif,1992,10(2):61-107.
[17]张毅,刘海燕,陈孝文,等.血液透析对慢性肾衰竭患者血浆白细胞介素13水平的影响.广东医学院学报,2003,21(2):115-117.
[18]Panichi V,Migliori M,De Pietro S,et al.C-reactive protein as a marker of chronic inflammation in uremic patients.Blood Purif,2000,18(3):183-190.
[19]毛海苹,朱兰英.透析膜对血浆细胞因子水平的影响及临床意义.肾脏病与透析移植杂志,1997,6(3):239-241.
[20]Witko-Sarsat V,Friedlander M,Capeillere-Blandin C,et al.Advanced oxidation protein products as a novel marker of oxidative st ress in uremia.Kidney Int,1996,49(5):1304-1313.
[21]Miyata T,Van Y,Kurokawa K,et al.Alterations in non-enzymatic biochemistry in uremia:Origin and significance of carbonyl stress in long-term uremia complications.Kidney Int,1999,55(2):389-399.
[22]Schetter V,Wieland E,Methe H,et al.Oxidative stress during dialysis:effect on ftee radical scavenging enzyme(FRSE)activities and glutathione(GSH)concentration in granulocytes.Nephrol Dial Transplant,1998,13(10):2588-2593.
[23]叶云浩,倪兆慧,钱家麒,等.终末期肾病微炎症状态和动脉粥样硬化的关系.中华肾脏病杂志,2004,20(3):173-176.
[24]Jan G.Oxidative strees in chronic renal failure.Nephrol Dial Transplant,2001,16:2135-2137.
[25]Pupim LB,Himmelfarb J,Mcmonagle E,et al.Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress.Kidney Int,2004,65(6):2371-2379.
[26]Kaysen GA.C-reactive protein:a story half told.Semin Dial,2000,13(3):143-146.
[27]Hou FF,Owen WF.Beta 2-microglobulin amyloidosis:role of monocytes/macrophages.Curr Opin Nephrol Hypertens,2002,11(4):417-421.
[28]余月明,侯凡凡,张训,等.慢性肾衰竭患者同型半胱氨酸血症氧化应激和微炎症反应间的关系及其在动脉粥样硬化中的作用.中华内科杂志,2004,43(4):292-295.
[29]Yukawa S,Mune M,Otani H.Vitamin E disturbances in chronic renal failure.Nippon Rinsho,1999,57(10):2366-2370.
[30]Witko-Sarsat V,Gausson V,Descamps-Latscha B,et al.Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 2003,84(5):11-14.
[31]梁敏,候凡凡,陈瑗.化学修饰蛋白质类尿毒症毒素的检测方法与评价.中华肾脏病杂志,2003,19:190-191.
[32]Kalousova M,Zima T,Tesar V,et al.Advanced glycation and products and advanced oxidation protein in hemodialyzed patients.Blood Purif,2002,20(6):531-536.
[33]Witko-Sarsat V,Friedlander M,Capeillere-Blandin C et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int,1996,49(5):1304-1313.
[34]Drueke T,Witko-Sarsat V,Massy ZA,et al.Iron Therapy,advanced oxidation protein products.and carotid artery intima media thickness in end stage renal disease.Circulation,2002,106(17):2212.
[35]Witko-Sarsat V,Friedlander M,Nguyen Khoa T,et al.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol,1998,161:2524-2532.
[36]彭侃夫,吴雄飞,王军霞,等.大剂量维生素C预冲透析器对血液透析患者晚期氧化蛋白产物的影响.中国血液净化,2006,5(6):311-346.
[37]Jonathan H,Stenvinkel P,Ikizler TA,et al.The elephant in uremia:Oxidant stress as a unifying concept of cardiovascular disease in uremia.Kidney Int,2002,62(5):1524-1538.
[38]Azzi A,Boscoboinik D,Hensey C.The protein kinase C family.Eur J Biochem,1992,208:547-557.
[39]Yoshikawa T,Yoshida N.Vitamin E and leucocyte-endothelial cell interaction.Antioxid Redox Signal,2000,2(4):821-825.
[40]Canaud B,Cristol J.-P,Morena M,et al.Imbalance of oxidants and antioxidants in heamodialysis patients.Blood Purif,1999,17(2-3):99-106.
[41]Miyazaki H,Matsuoka H,Itabe H,et al.Hemodialysis impairs endothelial function via oxidative stress:Effect of vitamin E-coated dialyzer.Circulation,2000,101(9):1002-1006.
[42]Omata M,Higuchi C,DemuraR,et al.Reduction of neutrophil activation by vitamin E modified dialyzer membranes.Nephron,2000,85(3):221-231.
[43]梁敏,刘俊,候凡凡,等.维生素E包被膜透析器对血透患者氧化状态的影响.中华肾脏病杂志,2003,19(4):259-260.
[44]Cristol JP,Bosc JY,Badiou S,et al.Erythropoietin and oxidative stress in haemodialysis:benefical effects of vitamin E supplemention.Nephrol Dial Transplant,1997,12(11):2312-2317.
[45]赵轶雯,王质刚.维生素E修饰的透析膜抗氧化作用临床研究.中国实用内科,2004,24(8):479-481.
[1]王海燕.慢性肾脏疾病防治的新概念.现代实用医学,2004,16(12):691-693.
[2]Giovanm,Pertosa,Giuseppe Grandaliano,et al.IL-6,IL-8,monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes.Kidney Int,1998;54:570-579.
[3]Yan-HD et al.Hemodialysis-related induction of interleukin-6 and interleukin-8 production by peripheral blood mononuclear cells.Hong Kong Journal of Nephrology 2001;3(1):33-37.
[4]严海东,李曼,钱正子,等.不同透析膜对血液透析患者外周血单个核细胞分泌IL-10的影响.中国医科大学学报,2001,30(2):144-146.
[5]许勇芝,唐德燊,梁东,等.慢性肾衰患者外周血IL-18水平及血液透析对其的影响.上海免疫学杂志,2003,23(1):50-52.
[6]Kawakami K.Interleukin-18 and host defense against infectiouspathogens.J Immunother,2002,25(Suppl 1):S12.
[7]Lebel-Binay S,Berger A,Zinzindohoue F,et al.Interleukin-18:biological properties and clinical implications.Eur Cytokine Netw,2000,11(1):15.
[8]Ahn HJ,Maruo S,Tomura M,et al.A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.J Immunol,1997,159(5):2125-2131.
[9]Barbulesou K,Becker C,Schlaak J F,et al.IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-γ promoter in primary CD4+T lymphocytes.J Immunol,1998,160(8):3642-3647.
[10]Smeltz RB,Chen J,Huli J,et al.Regulation of interleukin(IL)-18 receptor alpha chain expression on CD4(+)T cells during T helper(Th)1/Th2 differentiation.Critical downregulatory role of IL-4[J].J Exp M ed 2001,194(2):143-153.
[11]Son YI,Dallal RM,Mailliard RB,et al.Interleukin-18(IL-18)synergizes with IL-12 to enhance cytotoxicity,intergamma production and expansion of natural killer cells.Cancer Res,2001,61(3):884-888.
[12]Hashimoto W,Tanaka F,Robbins PD,et al.Natural killer,but not natural killer T,cells play a necessary role in the promotion of an innate antitumor response induced by IL-18.Int J Cancer,2003,103(4):508.
[13]CARMELO LIBETTA,et al.Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients Kidney International,2004,65:1473-1481.
[14]Di Felice A,Cappelli G,Facchini F,et al.Ultrafiltration and endotoxin removal from dialysis fluids.Kidney int,1993,41:201.
[15]Lufft V,Mahiout A,Shaldon S,et al.Retention of cytokine inducing substances inside high-flux dialyzers.Blood Purif,1996,14(1):26.
[16]Gerdes N,Sukhova GK,Libby P,et al.Expression of interleukin IL-18 and function IL-18receptor on human vascular endothelial cells,smooth muscle cells,and macrophages:implications for atherogenesis.J Exp Med,2002,195:245-257.
[17]Whitman SC,Ravisankar P,Elam H,et al.Exogenous interferon gamma enhances atherosclerosis in apolipoprotein E2/mice.Am J Pathol,2000,157(6):1819-1824.
[18]Zaremba J,Losy J.Interleukin-18 in acute ischaemic stroke patients[J].Neurol Sci,2003,24(3):17-24.
[19]朱志先,梁虹.现代心身疾病治疗学.北京:人民军医出版社,2002:197-197.
[20]Jiang Y,Harlocker SL,Molesh DA,et al.Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.Oncogene,2002,21(14):2270-2282.
[21]刘华峰,陈孝文等.原发性肾小球肾炎患者组织白介素18的表达.中华肾脏病杂志,2003,19(2):127-128.
[22]Melnikov VY,Ecder T,et al.Impaired IL-18 processing pretect caspase-1-deficient mice from ischemic acute renal failure[J].Clin Invest,2001,107(9):1145-1152
[23]Matsumoto K,Kanmatsuse K.Augmented interleukin 18 production by peripheral blood monocytes in patients with minimal change nephritic syndrome[J].Am J Nephrol, 2001,21(1):20-27.
[24] Mstsumoto K, Kanmatsuse K, Elevated interleukin-18 levels in the urine of nephritic patients[J]. Nephron, 2001,88(4):334-339.